These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31757021)

  • 21. Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial.
    Okuyama T; Eto Y; Sakai N; Minami K; Yamamoto T; Sonoda H; Yamaoka M; Tachibana K; Hirato T; Sato Y
    Mol Ther; 2019 Feb; 27(2):456-464. PubMed ID: 30595526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome).
    Motas S; Haurigot V; Garcia M; Marcó S; Ribera A; Roca C; Sánchez X; Sánchez V; Molas M; Bertolin J; Maggioni L; León X; Ruberte J; Bosch F
    JCI Insight; 2016 Jun; 1(9):e86696. PubMed ID: 27699273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of intracerebroventricular idursulfase-beta enzyme replacement therapy in mucopolysaccharidosis II murine model: heparan sulfate in cerebrospinal fluid as a clinical biomarker of neuropathology.
    Sohn YB; Ko AR; Seong MR; Lee S; Kim MR; Cho SY; Kim JS; Sakaguchi M; Nakazawa T; Kosuga M; Seo JH; Okuyama T; Jin DK
    J Inherit Metab Dis; 2018 Nov; 41(6):1235-1246. PubMed ID: 29978271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transferrin Receptor-Targeted Iduronate-2-sulfatase Penetrates the Blood-Retinal Barrier and Improves Retinopathy in Mucopolysaccharidosis II Mice.
    Imakiire A; Morimoto H; Suzuki H; Masuda T; Yoden E; Inoue A; Morioka H; Konaka T; Mori A; Shirasaka R; Kato R; Hirato T; Sonoda H; Minami K
    Mol Pharm; 2023 Nov; 20(11):5901-5909. PubMed ID: 37860991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modelling the neuropathology of lysosomal storage disorders through disease-specific human induced pluripotent stem cells.
    Kobolák J; Molnár K; Varga E; Bock I; Jezsó B; Téglási A; Zhou S; Lo Giudice M; Hoogeveen-Westerveld M; Pijnappel WP; Phanthong P; Varga N; Kitiyanant N; Freude K; Nakanishi H; László L; Hyttel P; Dinnyés A
    Exp Cell Res; 2019 Jul; 380(2):216-233. PubMed ID: 31039347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extension of the molecular analysis to the promoter region of the iduronate 2-sulfatase gene reveals genomic alterations in mucopolysaccharidosis type II patients with normal coding sequence.
    Brusius-Facchin AC; Abrahão L; Schwartz IV; Lourenço CM; Santos ES; Zanetti A; Tomanin R; Scarpa M; Giugliani R; Leistner-Segal S
    Gene; 2013 Sep; 526(2):150-4. PubMed ID: 23707223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxidative and nitrative stress and pro-inflammatory cytokines in Mucopolysaccharidosis type II patients: effect of long-term enzyme replacement therapy and relation with glycosaminoglycan accumulation.
    Jacques CE; Donida B; Mescka CP; Rodrigues DG; Marchetti DP; Bitencourt FH; Burin MG; de Souza CF; Giugliani R; Vargas CR
    Biochim Biophys Acta; 2016 Sep; 1862(9):1608-16. PubMed ID: 27251652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-myeloablative preconditioning with ACK2 (anti-c-kit antibody) is efficient in bone marrow transplantation for murine models of mucopolysaccharidosis type II.
    Yokoi T; Yokoi K; Akiyama K; Higuchi T; Shimada Y; Kobayashi H; Sato T; Ohteki T; Otsu M; Nakauchi H; Ida H; Ohashi T
    Mol Genet Metab; 2016 Nov; 119(3):232-238. PubMed ID: 27590924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impaired autophagosome clearance contributes to neuronal death in a piglet model of neonatal hypoxic-ischemic encephalopathy.
    Cui D; Sun D; Wang X; Yi L; Kulikowicz E; Reyes M; Zhu J; Yang ZJ; Jiang W; Koehler RC
    Cell Death Dis; 2017 Jul; 8(7):e2919. PubMed ID: 28703794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of donor chimerism to reduce the level of glycosaminoglycans following bone marrow transplantation in a murine model of mucopolysaccharidosis type II.
    Yokoi K; Akiyama K; Kaneshiro E; Higuchi T; Shimada Y; Kobayashi H; Akiyama M; Otsu M; Nakauchi H; Ohashi T; Ida H
    J Inherit Metab Dis; 2015 Mar; 38(2):333-40. PubMed ID: 25503568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enzyme augmentation therapy enhances the therapeutic efficacy of bone marrow transplantation in mucopolysaccharidosis type II mice.
    Akiyama K; Shimada Y; Higuchi T; Ohtsu M; Nakauchi H; Kobayashi H; Fukuda T; Ida H; Eto Y; Crawford BE; Brown JR; Ohashi T
    Mol Genet Metab; 2014 Feb; 111(2):139-46. PubMed ID: 24100247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mucopolysaccharidosis type II zebrafish model exhibits early impaired proteasomal-mediated degradation of the axon guidance receptor Dcc.
    Manzoli R; Badenetti L; Bruzzone M; Macario MC; Rubin M; Dal Maschio M; Roveri A; Moro E
    Cell Death Dis; 2024 Apr; 15(4):269. PubMed ID: 38627369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endoplasmic Reticulum and Lysosomal Quality Control of Four Nonsense Mutants of Iduronate 2-Sulfatase Linked to Hunter's Syndrome.
    Marazza A; Galli C; Fasana E; Sgrignani J; Burda P; Fassi EMA; Baumgartner M; Cavalli A; Molinari M
    DNA Cell Biol; 2020 Feb; 39(2):226-234. PubMed ID: 31895584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FGF signaling deregulation is associated with early developmental skeletal defects in animal models for mucopolysaccharidosis type II (MPSII).
    Bellesso S; Salvalaio M; Lualdi S; Tognon E; Costa R; Braghetta P; Giraudo C; Stramare R; Rigon L; Filocamo M; Tomanin R; Moro E
    Hum Mol Genet; 2018 Jul; 27(13):2262-2275. PubMed ID: 29648648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice.
    Ullman JC; Arguello A; Getz JA; Bhalla A; Mahon CS; Wang J; Giese T; Bedard C; Kim DJ; Blumenfeld JR; Liang N; Ravi R; Nugent AA; Davis SS; Ha C; Duque J; Tran HL; Wells RC; Lianoglou S; Daryani VM; Kwan W; Solanoy H; Nguyen H; Earr T; Dugas JC; Tuck MD; Harvey JL; Reyzer ML; Caprioli RM; Hall S; Poda S; Sanchez PE; Dennis MS; Gunasekaran K; Srivastava A; Sandmann T; Henne KR; Thorne RG; Di Paolo G; Astarita G; Diaz D; Silverman AP; Watts RJ; Sweeney ZK; Kariolis MS; Henry AG
    Sci Transl Med; 2020 May; 12(545):. PubMed ID: 32461331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of mucopolysaccharidosis type II by measurement of iduronate-2-sulfatase in dried blood spots and plasma samples.
    Dean CJ; Bockmann MR; Hopwood JJ; Brooks DA; Meikle PJ
    Clin Chem; 2006 Apr; 52(4):643-9. PubMed ID: 16497940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uptake of recombinant iduronate-2-sulfatase into neuronal and glial cells in vitro.
    Daniele A; Tomanin R; Villani GR; Zacchello F; Scarpa M; Di Natale P
    Biochim Biophys Acta; 2002 Dec; 1588(3):203-9. PubMed ID: 12393174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trehalose reduces retinal degeneration, neuroinflammation and storage burden caused by a lysosomal hydrolase deficiency.
    Lotfi P; Tse DY; Di Ronza A; Seymour ML; Martano G; Cooper JD; Pereira FA; Passafaro M; Wu SM; Sardiello M
    Autophagy; 2018; 14(8):1419-1434. PubMed ID: 29916295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glial degeneration with oxidative damage drives neuronal demise in MPSII disease.
    Zalfa C; Verpelli C; D'Avanzo F; Tomanin R; Vicidomini C; Cajola L; Manara R; Sala C; Scarpa M; Vescovi AL; De Filippis L
    Cell Death Dis; 2016 Aug; 7(8):e2331. PubMed ID: 27512952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy.
    Polito VA; Abbondante S; Polishchuk RS; Nusco E; Salvia R; Cosma MP
    Hum Mol Genet; 2010 Dec; 19(24):4871-85. PubMed ID: 20876612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.